Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071006 · ClinicalTrials.gov registry record · Phase 2
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00071006 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT00071006, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who have poor prognosis before entering the study.
Interventions
- DRUG AG-013736 (Axitinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2003-09 |
| Est. Completion | 2004-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00071006
The ClinicalTrials.gov registry entry for NCT00071006 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG-013736 (Axitinib) is the first listed.
NCT00071006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00071006 about?
NCT00071006 is a clinical study titled "AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)". The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who have poor prognosis before entering the study.
What is the current status of trial NCT00071006?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2003-09. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00071006?
The interventions under investigation include: AG-013736 (Axitinib) (DRUG).
Who is sponsoring clinical trial NCT00071006?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.